233 related articles for article (PubMed ID: 33387566)
21. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
[TBL] [Abstract][Full Text] [Related]
22. How do the top 12 pharmaceutical companies operate safety pharmacology?
Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
[TBL] [Abstract][Full Text] [Related]
23. A predictive index of biomarkers for ictogenesis from tier I safety pharmacology testing that may warrant tier II EEG studies.
Gauvin DV; Zimmermann ZJ; Yoder J; Harter M; Holdsworth D; Kilgus Q; May J; Dalton J; Baird TJ
J Pharmacol Toxicol Methods; 2018; 94(Pt 1):50-63. PubMed ID: 29751085
[TBL] [Abstract][Full Text] [Related]
24. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
25. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
26. Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
DaSilva JK; Breidenbach L; Deats T; Li D; Treinen K; Dinklo T; Kervyn S; Teuns G; Traebert M; Hempel K
J Pharmacol Toxicol Methods; 2020 Sep; 105():106919. PubMed ID: 33011055
[TBL] [Abstract][Full Text] [Related]
27. Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective.
Vahle JL; Anderson U; Blomme EAG; Hoflack JC; Stiehl DP
Regul Toxicol Pharmacol; 2018 Jul; 96():18-29. PubMed ID: 29679677
[TBL] [Abstract][Full Text] [Related]
28. Goals, design, timing, and future opportunities for nonclinical drug metabolism studies.
Miwa GT
Toxicol Pathol; 1995; 23(2):131-5. PubMed ID: 7569666
[TBL] [Abstract][Full Text] [Related]
29. Preclinical biomarker qualification.
Sauer JM; Porter AC;
Exp Biol Med (Maywood); 2018 Feb; 243(3):222-227. PubMed ID: 29171289
[TBL] [Abstract][Full Text] [Related]
30. Assessment of drug metabolites.
Izumi T
Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
[No Abstract] [Full Text] [Related]
31. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
[TBL] [Abstract][Full Text] [Related]
32. Qualification of translational safety biomarkers.
Sauer JM; Porter AC
Exp Biol Med (Maywood); 2021 Nov; 246(22):2391-2398. PubMed ID: 33757340
[TBL] [Abstract][Full Text] [Related]
33. Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?
Gao H; Jacobs A; White RE; Booth BP; Obach RS
AAPS J; 2013 Oct; 15(4):970-3. PubMed ID: 23821354
[TBL] [Abstract][Full Text] [Related]
34. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
[TBL] [Abstract][Full Text] [Related]
35. The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the DIA/ASA-BIOP Nonclinical Bayesian Working Group.
Faya P; Sondag P; Novick S; Banton D; Seaman JW; Stamey JD; Boulanger B
Pharm Stat; 2021 Mar; 20(2):245-255. PubMed ID: 33025743
[TBL] [Abstract][Full Text] [Related]
36. Safety biomarkers in preclinical development: translational potential.
Sasseville VG; Mansfield KG; Brees DJ
Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
[TBL] [Abstract][Full Text] [Related]
37. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
Holbrook M; Malik M; Shah RR; Valentin JP
J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
[TBL] [Abstract][Full Text] [Related]
38. Biomarker qualification via public-private partnerships.
Eck SL; Paul SM
Clin Pharmacol Ther; 2010 Jan; 87(1):21-3. PubMed ID: 20019697
[TBL] [Abstract][Full Text] [Related]
39. Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.
Mitra MS; Datta K; Hutchinson R; Nicolette JJ; Pettersen JC; Wegesser TC; Bercu JP
Regul Toxicol Pharmacol; 2021 Jun; 122():104895. PubMed ID: 33610610
[TBL] [Abstract][Full Text] [Related]
40. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
